Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗

September 27, 2021

The Week In Psychedelics:

Via Benzinga

Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases

September 27, 2021

Via Investor Brand Network

Topics Cannabis

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts

September 22, 2021

Via FinancialNewsMedia

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Which Psychedelic Stock ETF Is Right For You? ↗

September 18, 2021

This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.

Via Talk Markets

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0 ↗

September 15, 2021

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

National Suicide Prevention Week Shines Light on Psychedelic Treatments

September 09, 2021

Via FinancialNewsMedia

Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A ↗

September 07, 2021

Contents

Via Benzinga

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation ↗

August 31, 2021

A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr...

Via Benzinga

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗

August 30, 2021

Contents

Via Benzinga

Magic Mushroom Drug Stock Performances YTD ↗

August 29, 2021

Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”.

Via Talk Markets

MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients ↗

August 24, 2021

Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ:

Via Benzinga

Cramer Weighs In On RealReal, Affirm Holdings And More ↗

August 17, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said no to RealReal Inc (NASDAQ: REAL). He is not a buyer because there are too many of these guys. Mind Medicine (...

Via Benzinga

Push the Boundaries of DMT Therapy with Mind Medicine ↗

August 16, 2021

Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.

Via InvestorPlace

Topics Cannabis

MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline ↗

August 16, 2021

The psychedelics-focused medicines company MindMed (NASDAQ:

Via Benzinga

No Matter How the Pandemic Rolls, Mind Medicine Will Prevail ↗

August 11, 2021

While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling.

Via InvestorPlace

Which Psychedelic Drug Has The Most Commercial Potential? ↗

August 10, 2021

As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 ↗

August 05, 2021

Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:

Via Benzinga

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected ↗

August 02, 2021

Last week in Psychedelics:

Via Benzinga

Another Psychedelic Stock Debuts, As This One Sets Up In A Base ↗

July 29, 2021

Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange.

Via Investor's Business Daily

MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects ↗

July 29, 2021

Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such...

Via Benzinga

Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance" ↗

July 23, 2021

Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,

Via Benzinga

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

July 21, 2021

Via FinancialNewsMedia

Topics Law Enforcement

Mind Medicine Has More Obstacles Than Opportunities ↗

July 20, 2021

MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.

Via InvestorPlace

Psychedelic Decriminalization Creating Market Opportunities

July 12, 2021

Via FinancialNewsMedia

Topics Cannabis Law Enforcement

Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline ↗

July 12, 2021

Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n...

Via Benzinga

How To Invest In "Magic Mushrooms" (Psychedelics) ↗

July 09, 2021

A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.

Via Talk Markets

MindMed Stock Is Overvalued and Too Risky to Own ↗

July 08, 2021

MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.

Via InvestorPlace

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.